Trinity Biotech
TRIB
21 hedge funds and large institutions have $9.56M invested in Trinity Biotech in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
24% more capital invested
Capital invested by funds: $7.7M → $9.56M (+$1.86M)
5% more funds holding
Funds holding: 20 → 21 (+1)
0.03% more ownership
Funds ownership: 0.04% → 0.07% (+0.03%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$2.36M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$1.33M |
| 3 |
WCM
Whitefort Capital Management
New York
|
+$431K |
| 4 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$145K |
| 5 |
Morgan Stanley
New York
|
+$54.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$115K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$32.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$21.8K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$14.7K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$8.64K |
TRIB Hedge Fund Activity: Q1 2022 in Review
21 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2022, worth a combined $9.56M — up 24% from $7.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TRIB positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Stonehill Capital Management, adding an estimated $2.36M. The largest seller was Renaissance Technologies, cutting an estimated $115K.
- 21 institutional investors held Trinity Biotech (TRIB) as of Q1 2022, up from 20 in Q4 2021.
- Funds reported $9.56M of Trinity Biotech stock for Q1 2022, up 24% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q1 2022 and 2 closed out, a net change of +1 holder.
- The largest Trinity Biotech buyer in Q1 2022 was Stonehill Capital Management, an estimated $2.36M added.
- The largest Trinity Biotech seller in Q1 2022 was Renaissance Technologies, an estimated $115K sold.
Based on aggregated 13F filings for Q1 2022.